Xipere Generic: When Will Generic Triamcinolone Acetonide Be Available?
This page is aggregated from FDA records, court filings and company announcements. Coded and designed by Dr. Brian Staiger, PharmD, BCPS
Updated October 9, 2026 How we build our data
Xipere Generic at a Glance
Four quick answers from FDA records and our estimate.
- When is the first generic expected? April 2040 About 13.5 years away Why then?
- Has the FDA approved a generic? June 1982 30 companies approved
- When does the last patent end? April 2040 4 patents listed with the FDA
- Can you buy a generic today? Yes 96 companies list one in some form
A generic matching Xipere is expected to be available in April 2040, about 13.5 years away. A generic triamcinolone acetonide is already listed for sale in some form by 96 companies, so ask your pharmacy whether one matches Xipere.
Why April 2040?
It is when Xipere’s patent 12,419,833 ends. That patent covers the product’s formulation and a way of using it, and once it ends, generics can go on sale as soon as the FDA approves them. We rate it probable: more likely than not, but it can still move.
Will the generic cost less?
Usually. The FDA has already approved 30 companies to make a generic, and how many of them launch decides how far the price falls. See the price pattern
What should I do now?
Ask your pharmacy whether it can fill your prescription with a generic. It may look different from Xipere, but the active ingredient, strength and form are the same. What a generic means for you
Our month is only an estimate based on available information, so we never name a day.
Xipere by the Numbers
- Reason
- Patent expiresA patent that protects the brand runs out. After that, approved generics can be sold.
- How sure
- Probable More likely than not, but it can still move.
- Price competition
- None filed yet No filers on record
- Brand sales
- $9M a yearSmaller seller
- FDA approved 2021 October 2021 FDA Orange Book
- Patents listed 4 last runs to April 2040 FDA Orange Book
- Generics FDA-approved 30 companies, the first approved June 1982 FDA Orange Book
- Medicare Part D spent $37.6K in 2025, for 12 people CMS Part D Spending by Drug
- Medicaid prescriptions 37 in the last four reported quarters, $25.7K CMS Medicaid drug utilization, to Q1 2026
Xipere’s Road to a Generic
Xipere has had the market to itself since the FDA approved it in October 2021 (Bausch And Lomb Inc). Its 4 listed patents run to April 2040.
The first generic of Xipere is expected in April 2040.
Why that month: patent 12,419,833, on the product’s formulation and a way of using it, ends then.
Each bar runs from the brand’s approval to the day that protection ends. The green band is our projection for the first generic: a month, never a day, because legal dates move and a generic reaches shelves days to weeks after it is allowed. Sources: FDA Orange Book; the expected month from court records and company announcements.
Xipere Patents and FDA Protections
Every patent and exclusivity the FDA Orange Book lists for Xipere’s own applications. A protection running past the expected month does not mean the date is wrong: a settlement or a court ruling can let a generic in before a patent ends, and a patent on one formulation or use does not block every generic.
The one that matters for a generic launch: patent 12,419,833, which ends in April 2040, the month the first generic is expected.
| Patent | What it covers | Protects until | Status |
|---|---|---|---|
| 8,636,713 | A way of using it (U-3234) | May 2027 | Active |
| 9,636,332 | A way of using it (U-3234) | November 2033 | Active |
| 9,937,075 | The product’s formulation | May 2034 | Active |
| 12,419,833 Sets the expected month of generic availability | The product’s formulation; a way of using it (U-3234) | April 2040 | Active |
Source: FDA Orange Book, application 211950. Patent numbers open the patent on Google Patents.
Who Is Lined Up to Make Generic Triamcinolone Acetonide
Three steps stand between a brand and a generic you can buy: a company applies to the FDA, the FDA approves it, and the company starts selling it.
Applied to the FDA
No application count is on record for Xipere, but the FDA has already approved 30 companies (step 2), and every approval starts with an application.
Approved by the FDA
The FDA has approved generic versions from 30 companies, the first in June 1982. Approved is not the same as on sale: patents, a settlement or the company’s own plans can still hold a launch.
For Sale in Pharmacies
Yes. A generic triamcinolone acetonide in some form is listed for sale by 96 companies. Ask your pharmacy whether it can fill your prescription with it.
A-S Medication Solutions, Advanced Rx Pharmacy of Tennessee, LLC, Alembic Pharmaceuticals Inc., Alembic Pharmaceuticals Limited, Allegiant Health, Amazon.com Services LLC and 34 more
| Company | First approved | Strengths | Rated |
|---|---|---|---|
| Sun Pharma Canada Inc | December 1982 | 0.025%, 0.1%, 0.5% | AT |
| Crown Laboratories Inc | March 1984 | 0.025%, 0.1%, 0.5% | AT |
| Pharmobedient Consulting LLC | April 1985 | 0.025%, 0.1% | AT |
| Cosette Pharmaceuticals Nc Laboratories LLC | August 1986 | 0.025%, 0.1%, 0.5% | AT |
| Taro Pharmaceutical Industries Ltd | November 1997 | 0.1% | AT |
| Fougera Pharmaceuticals Inc | April 2003 | 0.025%, 0.1%, 0.5% | AT |
| Micro Labs Ltd | June 2006 | 0.025%, 0.1% | AT |
| Perrigo Pharma International Dac | July 2009 | 0.055MG/SPRAY | – |
| Rising Pharma Holdings Inc | July 2010 | 0.1%, 0.147MG/GM | AT |
| Epic Pharma LLC | May 2013 | 0.025%, 0.1% | AT |
| Padagis Israel Pharmaceuticals Ltd | April 2015 | 0.05%, 0.147MG/GM | AT |
| Encube Ethicals Private Ltd | May 2016 | 0.05%, 0.1%, 0.5% | AT |
| Sciegen Pharmaceuticals Inc | August 2016 | 0.1%, 0.147MG/GM | AT |
| Chartwell Rx Sciences LLC | February 2017 | 0.025%, 0.05%, 0.1%, 0.5% | AT |
| Amneal Eu Ltd | December 2017 | 40MG/ML | AB |
| Alkem Laboratories Ltd | December 2017 | 0.025%, 0.1%, 0.5% | AT |
| Macleods Pharmaceuticals Ltd | May 2018 | 0.025%, 0.05%, 0.1%, 0.5% | AT |
| Teva Pharmaceuticals USA Inc | October 2018 | 0.025%, 0.1%, 0.5%, 40MG/ML | AB |
| Strides Pharma Global Pte Ltd | February 2019 | 0.025%, 0.05%, 0.1%, 0.5% | AT |
| Aurobindo Pharma Ltd | March 2020 | 0.055MG/SPRAY, 0.1%, 0.5% | – |
| Quagen Pharmaceuticals LLC | July 2020 | 0.025%, 0.1% | AT |
| Senores Pharmaceuticals Inc | November 2020 | 0.05% | AT |
| Long Grove Pharmaceuticals LLC | January 2022 | 40MG/ML | AB |
| Eugia Pharma Specialities Ltd | July 2022 | 40MG/ML | AB |
| Mylan Laboratories Ltd | November 2022 | 40MG/ML | AB |
| Apotex Inc | January 2023 | 0.055MG/SPRAY | – |
| Hikma Pharmaceuticals USA Inc | December 2024 | 40MG/ML | AB |
| Dr Reddys Laboratories Ltd | March 2025 | 10MG/ML, 40MG/ML | AB |
| Alembic Pharmaceuticals Ltd | October 2025 | 40MG/ML | AB |
| Padagis US LLC | Not given | 0.025%, 0.1%, 0.5% | AT |
| Actavis Mid Atlantic LLC discontinued | June 1982 | 0.1% | – |
| Alpharma US Pharmaceuticals Division discontinued | June 1982 | 0.025%, 0.1%, 0.5% | – |
| Pharmafair Inc discontinued | August 1982 | 0.025%, 0.1%, 0.5% | – |
| Savage Laboratories Inc Div Altana Inc discontinued | March 1983 | 0.025%, 0.1%, 0.5% | – |
| Ambix Laboratories Div Organics Corp America discontinued | May 1983 | 0.025% | – |
| Pharmaderm Div Altana Inc discontinued | July 1983 | 0.025%, 0.1%, 0.5% | – |
| Morton Grove Pharmaceuticals Inc discontinued | September 1983 | 0.025%, 0.1%, 0.5% | – |
| Astellas Pharma US Inc discontinued | October 1984 | 0.025%, 0.1%, 0.5%, 0.5% **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | – |
| Ivax Pharmaceuticals Inc discontinued | November 1988 | 0.025%, 0.1%, 0.5% | – |
| Topiderm Inc discontinued | February 1989 | 0.025%, 0.1%, 0.5% | – |
| Cmp Pharma Inc discontinued | March 1995 | 0.05% | – |
| Caplin Steriles Ltd discontinued | May 2009 | 10MG/ML | – |
| Sandoz Inc discontinued | June 2009 | 40MG/ML | – |
| Beach Products Inc discontinued | July 2016 | 0.025% | – |
| Glenmark Pharmaceuticals Ltd discontinued | July 2016 | 0.1%, 0.5% | – |
| Glenmark Specialty SA discontinued | August 2017 | 0.1% | – |
| Delcor Asset Corp discontinued | Not given | 0.025% **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, 0.1%, 0.1% **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, 0.5%, 0.5% **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | – |
| Solvay Pharmaceuticals discontinued | Not given | 0.1% | – |
| Watson Laboratories Inc discontinued | Not given | 40MG/ML | – |
Sources: how many companies have applied, from court records and company announcements; approved generics from the FDA Orange Book; tentative approvals from Drugs@FDA; what is for sale from the FDA NDC Directory. The FDA does not disclose an application before it approves it (21 CFR 314.430).
Xipere Price: What Pharmacies Pay and What Generics Usually Do
What a Generic Could Cost
How we estimate it. The national survey of what pharmacies pay (NADAC) has no recent price for Xipere, so we cannot show dollars. Here is the FDA’s finding of how far the price pharmacies pay usually falls as generic companies join: about 31% with one company, 44% with two, 73% with four and over 95% with six or more (the typical drop for every drug whose first generic came out from 2015 to 2017).
Median prices pharmacies paid for the generic (invoice prices), compared with the brand’s price before generic entry, from FDA’s 2019 analysis “Generic Competition and Drug Prices”. At the manufacturer’s price FDA found steeper drops (about 39%, 54%, 79% and over 95%), the figures quoted elsewhere on this tracker. A typical pattern, not a price quote for this medicine.
What Medicare and Medicaid Spend on Xipere
Big public spending is part of why generic makers line up for a medicine, and why its first generic matters beyond the pharmacy counter. Figures are before manufacturer rebates, which are confidential.
Medicare Part D Spending
What Medicare drug plans spent on Xipere, before manufacturer rebates.
- $37.6K
- 2025, the whole year
For 12 people, about $1,880 per prescription fill
See the numbers
| Period | Spending | People | Per fill |
|---|---|---|---|
| 2025 | $37,608 | 12 | $1,880.38 |
Source: CMS Medicare Part D Spending by Drug, matched by the brand name Xipere only, so no generic is counted in it. What CMS says it is used for: Drug uses not available.
Medicaid Prescriptions by Quarter
37 prescriptions in the four quarters to Q1 2026, $25.7K paid.
See the numbers
| Quarter | Prescriptions | Medicaid paid |
|---|---|---|
| Q1 2026 | 0 | $0 |
| Q4 2025 | 11 | $1,903 |
| Q3 2025 | 15 | $13,449 |
| Q2 2025 | 11 | $10,338 |
| Q1 2025 | 16 | $15,876 |
Source: CMS Medicaid State Drug Utilization Data, over Xipere’s own package codes.
Xipere Strengths and Forms
| Strength | Form | How it is taken | Approved | Status |
|---|---|---|---|---|
| 40MG/ML | Suspension | Injection | October 2021 | Prescription reference product |
Source: FDA Orange Book, Bausch And Lomb Inc. Listed for sale today by Bausch & Lomb Incorporated and Clearside Biomedical, Inc. (FDA NDC Directory).
Xipere NDC Codes and Packages
Each Xipere package sold today has its own NDC, the product number printed on the box and on the pharmacy label. Open one to see that package’s details, what pharmacies pay for it and its patent timeline.
| NDC | Product | Package | Company |
|---|---|---|---|
| 71565-0040-01 | 40 mg/mL injection, suspension | vial of .9 mL | Clearside Biomedical, Inc. |
| 71565-0040-99 | 40 mg/mL injection, suspension | vial of .9 mL | Clearside Biomedical, Inc. |
| 24208-0040-01 | TRIAMCINOLONE ACETONIDE 40 mg/mL injection, suspension | vial of .9 mL | Bausch & Lomb Incorporated |
| 24208-0040-01 | TRIAMCINOLONE ACETONIDE 40 mg/mL injection, suspension | vial of .9 mL | Bausch & Lomb Incorporated |
| 24208-0040-40 | TRIAMCINOLONE ACETONIDE 40 mg/mL injection, suspension | vial of .9 mL | Bausch & Lomb Incorporated |
| 24208-0040-40 | TRIAMCINOLONE ACETONIDE 40 mg/mL injection, suspension | vial of .9 mL | Bausch & Lomb Incorporated |
Source: the FDA NDC Directory, current listings only. Only packages sold under Xipere’s own FDA approval (NDA 211950) are listed, never a generic. Some codes belong to companies that repackage Xipere: it is the same medicine in a different package.
What a Generic Xipere Means for You
Nothing Changes Until It Is in Pharmacies
A generic is listed for sale now, so your pharmacy may already be able to fill your prescription with it.
Your Pharmacy May Switch You Automatically
Every state lets pharmacists fill a brand-name prescription with an FDA-approved generic rated as equivalent to it, and about 19 states require them to, unless your prescriber writes “dispense as written” or “brand medically necessary” on the prescription. Some states ask the pharmacist to tell you, or to get your OK first. A study of every state’s law has the details.
It Will Probably Look Different
US trademark law does not let a generic look exactly like the brand, so the color, shape or markings usually change. The active ingredient, strength and form are the same. An “authorized generic,” made by or for the brand’s own company, can look identical. The FDA explains.
Your Insurance May Change Too
Once a lower-cost version is available, many insurance plans charge more for the brand, or stop covering it. Your plan’s drug list (formulary) says how.
Questions people ask about Xipere
Is there a generic for Xipere right now?
Yes. The FDA NDC Directory lists a generic triamcinolone acetonide in some form from 96 companies. Ask your pharmacy whether it can fill your prescription with it.
When will Xipere go generic?
April 2040 is the expected month, and that is probable but not certain. It is when Xipere’s patent 12,419,833 ends. That patent covers the product’s formulation and a way of using it, and once it ends, generics can go on sale as soon as the FDA approves them.
Will generic triamcinolone acetonide be the same as Xipere?
Yes in the ways that matter: the same active ingredient, strength and form, with proof that it reaches your blood the same way. Inactive ingredients can differ, which is why some people notice a different look or taste.
How much will the generic cost?
Nobody can say for sure before launch. The FDA has already approved 30 companies to make a generic, and how many of them launch decides how far the price falls.
Has the FDA approved a generic Xipere?
Yes. The FDA Orange Book lists approved generic versions from 30 companies, the first approved in June 1982: Sun Pharma Canada Inc, Crown Laboratories Inc, Pharmobedient Consulting LLC, Cosette Pharmaceuticals Nc Laboratories LLC and 26 more. Approved is not the same as on sale: patents, a settlement or the company’s own plans can still hold a launch.
When does the Xipere patent expire?
The FDA Orange Book lists 4 patents for Xipere; the last runs to April 2040. The one behind the expected month is patent 12,419,833, which ends in April 2040. A patent date is not the launch date: settlements and court rulings often bring a generic earlier, and FDA approval or a company’s own plans can make it later. The expected month on this page (April 2040) weighs all of that.
Changes to This Projection
- First generic expected April 2040 on this month’s schedule. A line is added here whenever a monthly update moves the month, the reason or how sure it is.
Every change to the expected month is logged here with the month we saw it.
Also Going Generic
- VeltassaPatiromer Sorbitex Calcium2030 to 2031
- NexteroneAmiodarone HydrochlorideFebruary 2033
- DelstrigoDoravirine, Lamivudine, and Tenofovir Disoproxil Fumarate2035 to 2036
- RozlytrekEntrectinibFebruary 2035
- IngrezzaValbenazine TosylateMarch 2038
- AdlarityDonepezilAugust 2038
About Xipere
- Generic name triamcinolone acetonide
- Company Bausch And Lomb Inc
- Hard to copy Inhalers, injectables, patches and other hard-to-copy products. Fewer companies attempt them and dates slip more often.
- More drugs Brand-name drugs starting with X
- Have a question? A pharmacist answers, free. Ask about Xipere
Sources. The expected month: FDA Paragraph IV Patent Certifications list, federal court records, company announcements and securities filings (settlement dates, launch plans, sales). The record on this page: FDA Orange Book, Drugs@FDA (tentative approvals), FDA NDC Directory, CMS Medicare Part D Spending by Drug, Medicaid State Drug Utilization Data, FDA, Generic Competition and Drug Prices (2019). Updated October 9, 2026. Information, not medical advice.